STARLIMS Acquires International Distribution Partners
News Mar 11, 2012
As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin America and Africa, STARLIMS Technologies, an Abbott company, has announced the acquisition of several longtime distribution partners. These acquisitions include STARLIMS's French distributor Varilab; operations of two privately held Spanish businesses, now operating as STARLIMS Iberica; a privately held Dutch company, now operating as STARLIMS Netherlands, with a branch office in Solna, Sweden; and the business of its Israeli distribution partner, STARLIMS Israel, Ltd. In addition, the company established STARLIMS Germany GmbH, with offices in Witten, Germany, to provide direct support for its German and Swiss customers.
"The successful completion of these transactions represents Abbott's commitment to invest in and accelerate the growth of STARLIMS's core business," said Isaac Friedman, head of Abbott's STARLIMS business. "With these acquisitions, we now have more than 100 experienced LIMS engineers in the region allowing us to better serve our fast-growing European customer base and further strengthen our position as a leading provider of laboratory information management systems in Europe and other important markets."
According to a statement from the company, since its acquisition by Abbott in March 2010, STARLIMS has accelerated its worldwide sales growth and R&D spending. This has resulted in the addition of more than 150 customers across its global operations, including major government accounts in the fields of forensics, public health and utilities, as well as multinational manufacturing and pharmaceutical companies.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
The architecture of each person’s brain is unique, and differences may influence how quickly people can complete various cognitive tasks.o learn more, scientists are developing a new tool — computational models of the brain — to simulate how the structure of the brain may impact brain activity and, ultimately, human behavior.READ MORE